Tags

Type your tag names separated by a space and hit enter

Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1.
Immunol Lett. 2006 Apr 15; 104(1-2):83-8.IL

Abstract

In the in vitro infected B-cells six EBV-encoded nuclear antigens (EBNA-1-6) and three latent membrane proteins (LMP-1, -2A, -2B) are expressed (type III latency). In addition, other restricted forms of latency occur in the EBV-carrying malignancies. In Burkitt lymphoma (BL) only EBNA-1 is expressed (type I), while in Hodgkin lymphoma (HL), T-, and NK-lymphoma, and nasopharyngeal carcinoma EBNA-1 and LMPs are expressed (type II). B-cells with these three expression patterns have been detected in healthy virus carriers. While in type III latency two viral transcriptional activators, EBNA-2 and -5, are responsible for LMP-1 expression, the mechanism that controls the expression of LMP-1 in type II latent cells is not known. In order to study the interaction of EBV- and HL-derived cells, we studied the in vitro EBV-converted subline of the KMH2 cells that express only EBNA-1 and LMP-2A. Interestingly, exposure of the KMH2-EBV cells to CD40-ligand and IL-4 induced LMP-1 expression, in the absence of EBNA-2. In BL cell lines lacking EBNA-2 another cytokine, IL-10, could induce LMP-1 expression. IL-10 induced LMP-1 also in tonsillar B-cells infected with the EBNA-2-deleted virus strain P3HR-1. Our results show that cytokines are responsible for the expression of LMP-1 in type II latent B-cells. These signals are available in the germinal center environment and in the granulation tissue of HLs. Based on these results we propose that LMP-1 expression is induced by extracellular signals and is not a constitutive characteristic of the EBV-carrying type II B-cells. Cytokine mediated induction of LMP-1 may also explain the heterogeneous expression of this viral gene seen in normal and malignant cells.

Authors+Show Affiliations

Microbiology and Tumor Biology Center, Karolinska Institute, S-17177 Stockholm, Sweden. Kis.Lorand.Levente@mtc.ki.seNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

16386314

Citation

Kis, Loránd L., et al. "Cytokine Mediated Induction of the Major Epstein-Barr Virus (EBV)-encoded Transforming Protein, LMP-1." Immunology Letters, vol. 104, no. 1-2, 2006, pp. 83-8.
Kis LL, Takahara M, Nagy N, et al. Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1. Immunol Lett. 2006;104(1-2):83-8.
Kis, L. L., Takahara, M., Nagy, N., Klein, G., & Klein, E. (2006). Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1. Immunology Letters, 104(1-2), 83-8.
Kis LL, et al. Cytokine Mediated Induction of the Major Epstein-Barr Virus (EBV)-encoded Transforming Protein, LMP-1. Immunol Lett. 2006 Apr 15;104(1-2):83-8. PubMed PMID: 16386314.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1. AU - Kis,Loránd L, AU - Takahara,Miki, AU - Nagy,Noémi, AU - Klein,George, AU - Klein,Eva, Y1 - 2005/12/01/ PY - 2005/10/30/received PY - 2005/10/30/revised PY - 2005/11/08/accepted PY - 2006/1/3/pubmed PY - 2006/5/26/medline PY - 2006/1/3/entrez SP - 83 EP - 8 JF - Immunology letters JO - Immunol Lett VL - 104 IS - 1-2 N2 - In the in vitro infected B-cells six EBV-encoded nuclear antigens (EBNA-1-6) and three latent membrane proteins (LMP-1, -2A, -2B) are expressed (type III latency). In addition, other restricted forms of latency occur in the EBV-carrying malignancies. In Burkitt lymphoma (BL) only EBNA-1 is expressed (type I), while in Hodgkin lymphoma (HL), T-, and NK-lymphoma, and nasopharyngeal carcinoma EBNA-1 and LMPs are expressed (type II). B-cells with these three expression patterns have been detected in healthy virus carriers. While in type III latency two viral transcriptional activators, EBNA-2 and -5, are responsible for LMP-1 expression, the mechanism that controls the expression of LMP-1 in type II latent cells is not known. In order to study the interaction of EBV- and HL-derived cells, we studied the in vitro EBV-converted subline of the KMH2 cells that express only EBNA-1 and LMP-2A. Interestingly, exposure of the KMH2-EBV cells to CD40-ligand and IL-4 induced LMP-1 expression, in the absence of EBNA-2. In BL cell lines lacking EBNA-2 another cytokine, IL-10, could induce LMP-1 expression. IL-10 induced LMP-1 also in tonsillar B-cells infected with the EBNA-2-deleted virus strain P3HR-1. Our results show that cytokines are responsible for the expression of LMP-1 in type II latent B-cells. These signals are available in the germinal center environment and in the granulation tissue of HLs. Based on these results we propose that LMP-1 expression is induced by extracellular signals and is not a constitutive characteristic of the EBV-carrying type II B-cells. Cytokine mediated induction of LMP-1 may also explain the heterogeneous expression of this viral gene seen in normal and malignant cells. SN - 0165-2478 UR - https://www.unboundmedicine.com/medline/citation/16386314/Cytokine_mediated_induction_of_the_major_Epstein_Barr_virus__EBV__encoded_transforming_protein_LMP_1_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0165-2478(05)00347-0 DB - PRIME DP - Unbound Medicine ER -